HC Wainwright Starts Travere Therapeutics, Inc. (TVTX) at Buy on FILSPARI Breakthroughs
Travere Therapeutics, Inc. (NASDAQ:TVTX) is among the 10 Best Growth Stocks Under $100 to Buy Now. HC Wainwright & Co., a leading investment bank, has initiated a 'Buy' rating for Travere Therapeutics, Inc. (NASDAQ:TVTX), with a price target of $30, signaling an upside of around 100%. This confidence in the company underscores its position in the pharmaceutical sector.
The company has just announced plans to present three new abstracts underscoring the impact of FILSPARI (sparsentan) in rare kidney disease at the International Podocyte Conference, taking place in Hamburg, Germany. The findings of FILSPARI, showcasing advanced reductions in urinary BAFF and sC5b9, along with dips in the proinflammatory and profibrotic biomarkers, signal a step forward in the treatment of IgAN.
A laboratory technician working on a solution of rare diseases, housed in a cholic acid capsule.
With net sales of FILSPARI increasing 182% year-over-year and the successful approval of FILSPARI in Europe and the UK, analysts have little doubt about the company's potential. Since the major revenue contribution comes from FILSPARI, the rising popularity and increasing adoption among nephrologists mean that Travere Therapeutics, Inc. (NASDAQ:TVTX) can continue to leverage a product that is quite differentiated.
Travere Therapeutics, Inc. (NASDAQ:TVTX) is a biopharmaceutical company incorporated in 2008. This California-based giant recognizes, develops, and commercializes therapies for people suffering from rare kidney and metabolic diseases in the United States.
While we acknowledge the potential of TVTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
From Scrubs to Coats: Zenir Introduces New White Lab Coat Collection for Healthcare Professionals
Zenir, the trusted name in premium medical scrubs, has officially expanded its product lineup with the launch of its first white lab coats available now for both men and women in short and long lengths. Torrance, California--(Newsfile Corp. - June 14, 2025) - Zenir, the trusted name in premium medical scrubs, has officially expanded its product lineup with the launch of its first white lab coats available now for both men and women in short and long lengths. Known for combining functional innovation with elevated style, Zenir continues to raise the standard for medical workwear with this new release. From Scrubs to Coats: Zenir Introduces New White Lab Coat Collection for Healthcare Professionals To view an enhanced version of this graphic, please visit: The newly launched white lab coats faithfully embody Zenir's philosophy of comfort, practicality, and refined style. The short-length lab coat is engineered with a three-dimensional pattern that naturally facilitates shoulder and arm movement ideal for dynamic, active roles while the long lab coat features a subtly cinched waistline and matte hidden snap buttons to deliver a sleek, professional silhouette in clinical settings. Meticulously designed storage details, such as a dedicated pen holder in the chest pocket and an inner pocket for smartphones, balance functionality with clean design. Optimized for fast-paced healthcare environments, this collection not only meets workplace requirements but also offers a range of fits and style options to suit every body shape and individual preference. Already recognized for its high-performance scrubs, Zenir is a brand trusted by thousands in the healthcare industry and has sold more than 3 million units globally. The brand has earned its reputation for premium-quality scrubs that are breathable, durable, wrinkle-resistant, and moisture-wicking, now extended to its latest line of white lab coats. As Zenir continues to grow its presence beyond Korea, this expansion into white lab coats marks a milestone in Zenir's commitment to offering a complete spectrum of medical workwear solutions. With thoughtfully tailored cuts, sustainable production using GRS-certified recycled fibers, and a design-first approach, Zenir's new white lab coats are built for professionals who expect more from their daily uniform. For more details, visit Contact Info:Name: Jiho JangEmail: admin@ ZenirWebsite: To view the source version of this press release, please visit
Business Wire
an hour ago
- Business Wire
Perma-Pipe International Holdings, Inc.公布2025會計年度第一季財務業績
德州斯普林--(BUSINESS WIRE)--(美國商業資訊)-- Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH)今天公布了截至2025年4月30日的第一季財務業績。 總裁兼執行長Saleh Sagr指出：「第一季銷售額為4670萬美元，較去年同期的3430萬美元成長1240萬美元，增幅36.2%。歸屬於普通股的淨收入為500萬美元，較上年第一季的140萬美元成長360萬美元，增幅達243%。」 Sagr先生繼續說道：「目前未完成訂單為1.311億美元，相較2025年1月31日的1.381億美元減少700萬美元。然而，相較2024年4月30日的6310萬美元，該公司的未完成訂單大幅增加6800萬美元，增幅達108%。我們對現有未完成訂單水準感到鼓舞，其仍為去年第一季末報告之未完成訂單水準的兩倍以上。」 總裁兼執行長Saleh Sagr表示：「第一季業績代表公司實現了前所未見的業務表現，無論是銷售額還是歸屬於普通股的淨收入，均為2017年從MFRI轉變為Perma-Pipe以來第一季的最高水準。此外，第一季歸屬於普通股的淨收入約占公司2024會計年度全年業績的55%。」 Sagr先生評論道：「我們對各市場的業務活動水準感到滿意，這推動了第一財季整體銷售額和收益的成長。此外，美洲和中東及北非(MENA)地區的業績表現令人振奮，兩個地區在第一季取得了不相上下的業績。」 Sagr先生總結道：「公司第一季業績的強勁表現為2025會計年度剩餘季度提供了顯著的發展動力。我們認為公司已做好充分準備，將繼續利用這一動力，進一步參與MENA地區的發展計畫，並在北美地區取得更多市場佔有率。」 2025會計年度第一季業績 截至2025年4月30日的三個月和2024年4月30日的三個月，淨銷售額分別為4670萬美元和3430萬美元。增加的1240萬美元（增幅36%）主要是由於中東和北美的銷售量增加。 截至2025年4月30日的三個月和2024年4月30日的三個月，毛利分別為1670萬美元（占淨銷售額的36%）和1050萬美元（占淨銷售額的31%）。增加的620萬美元主要是由於業務量增加以及產品組合帶來的更高利潤率。 截至2025年4月30日的三個月和2024年4月30日的三個月，一般和行政支出分別為770萬美元和610萬美元。增加的160萬美元是由於本季度薪資支出和專業服務費的增加。 截至2025年4月30日的三個月和2024年4月30日的三個月，銷售支出保持穩定，分別為110萬美元和120萬美元。 截至2025年4月30日的三個月和2024年4月30日的三個月，淨利息支出保持穩定，分別為40萬美元和50萬美元。 截至2025年4月30日的三個月和2024年4月30日的三個月，其他支出保持穩定，均低於10萬美元。 截至2025年4月30日的三個月和2024年4月30日的三個月，公司的有效稅率(ETR)分別為21%和30%。ETR的變動是由於各司法管轄區的盈虧構成不同。 截至2025年4月30日的三個月和2024年4月30日的三個月，歸屬於普通股的淨收入分別為500萬美元和140萬美元。增加的360萬美元主要是由於本季度銷售量增加以及更好的專案執行。 關於Perma-Pipe International Holdings, Inc. Perma-Pipe International Holdings, Inc.（簡稱「公司」）是針對石油和天然氣採集、區域供熱和製冷以及其他應用的預絕緣管道和洩漏偵測系統的全球領導者。公司利用其廣泛的工程和製造專長開發管道解決方案，以解決多種液體安全高效運輸的複雜挑戰。公司總計在六個國家的14個據點經營業務。 前瞻性陳述 本新聞稿中包含的某些陳述和其他資訊可以透過使用前瞻性術語來辨識，構成《1933年證券法》（修訂版）第27A條和《1934年證券交易法》（修訂版）第21E條所定義的「前瞻性陳述」，並受到其中包含的安全港條款的約束，包括但不限於有關公司未來預期業績和營運的陳述。這些陳述應被視為受到公司營運和業務環境中存在的許多風險和不確定性的影響。這些風險和不確定因素包括但不限於以下內容：(i)石油和天然氣價格的波動及其對公司產品客戶訂單量的影響；(ii)公司以優惠價格購買原物料並與供應商保持良好關係的能力；(iii)使用公司產品的政府專案支出減少，以及公司的非政府客戶在流動性和獲得資本資金方面面臨挑戰；(iv)公司償還債務和續延即將到期的國際信貸便利的能力；(v)公司有效執行策略計畫以及實現持續盈利和正現金流的能力；(vi)公司收取與中東專案有關的長期應收帳款的能力；(vii)公司解讀稅收法規和立法變化的能力；(viii)公司利用其淨經營虧損結轉的能力；(ix)由於公司在「超時」確認收入時估計不準確，導致以前記錄的收入和利潤逆轉；(x)公司未能建立和維護有效的財務報告內部控制；(xi)公司產品的訂單接收、執行、交付和驗收時間；(xii)公司就大額合約的進度帳單安排進行成功談判的能力；(xiii)現有競爭對手的激進定價以及新競爭對手進入公司經營的市場；(xiv)公司製造無潛在缺失產品的能力，以及向可能為公司提供有缺失材料的供應商追償的能力；(xv)公司未完成訂單中訂單的減少或取消；(xvi)公司國際業務營運特有的風險和不確定性；(xvii)公司吸引和留住高階管理人員和關鍵員工的能力；(xviii)公司實現成長計畫預期效益的能力；(xix)流行病和其他公共衛生危機對公司及其營運的影響；以及(xx)網路安全威脅對公司資訊技術系統的影響。請股東、潛在投資人和其他讀者在評估前瞻性陳述時仔細考量這些因素，並注意不要過分依賴此類前瞻性陳述。此處所做的前瞻性陳述僅反映本新聞稿發表之日的情況。無論是由於新資訊、未來事件還是其他原因，我們概不承擔公開更新任何前瞻性陳述的義務。有關可能影響我們業績的因素的更多詳細資訊，請參閱我們向美國證券交易委員會遞交的文件，這些文件可在 以及我們網站的「投資人中心」(Investor Center)部分( 公司財政年度截止日為每年1月31日。本報告所述2025年、2024年及2023年財務資料，分別對應截至2026年1月31日、2025年1月31日及2024年1月31日止的財務年度。 有關公司截至2025年1月31日財政年度財務業績的更多資訊，包括管理層對公司財務狀況和經營成果的討論與分析，載於公司截至2025年1月31日的10-Q表年報，這些資料將於本報告發表之日或前後遞交給美國證券交易委員會，並可透過 和 查閱。如欲瞭解更多資訊，請造訪公司網站。 PERMA-PIPE INTERNATIONAL HOLDINGS, INC.及子公司 簡明合併資產負債表 （以千為單位） （未經稽核） 2025年4月30日 2025年1月31日 資產 流動資產 $ 120,700 $ 108,802 長期資產 57,615 56,439 資產總額 $ 178,315 $ 165,241 負債與股東權益 流動負債 $ 61,751 $ 54,063 長期負債 26,459 28,073 負債總額 88,210 82,136 非控制權益 12,238 10,967 股東權益 77,867 72,138 負債和權益總額 $ 178,315 $ 165,241 Expand 免責聲明：本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用，煩請參照原文，原文版本乃唯一具法律效力之版本。
Yahoo
an hour ago
- Yahoo
Veteran fund manager issues dire stock market warning
Veteran fund manager issues dire stock market warning originally appeared on TheStreet. The stock market loves climbing a wall of worry. We've certainly seen that over the past two months. Despite worry over mounting U.S. debt and tariff impacts on inflation and the economy, the S&P 500 has rallied 20%. Technology stocks have done even better. The Nasdaq Composite, home to most tech leaders, is up 27%. The rally since President Trump paused most reciprocal tariffs announced on April 2, so-called "Liberation Day," for 90 days has been impressive. However, there's good reason for concern, especially since the S&P 500 is challenging all-time highs and its valuation is arguably becoming frothy risk that stocks could lose some of their luster after their rally has caught the attention of many Wall Street veterans, including long-time hedge fund manager Doug Kass. Kass has been navigating the markets since the 1970s, including as research director for Leon Cooperman's Omega Advisors, and his experience through good and bad times helped him correctly predict the sell-off earlier this year and the market bottom in April. This week, Kass updated his stock market outlook, including a surprisingly long list of red flags for why investors should be cautious. The best set-up for tantalizing returns is a market that's oversold enough to have reset forward price-to-earnings ratios to levels near the lower end of their historical averages. In February, when stocks were notching all-time highs right before the tariff-fueled reckoning, the S&P 500's P/E ratio eclipsed 22, and most sentiment measures were flashing sell-off through early April erased much of that frothiness, driving the S&P 500's P/E ratio to 19 and below five-year averages of 19.9 — not bargain-basement priced, but low enough to help catapult stocks from severely oversold readings. As a reminder, CNN's Fear & Greed indicator was at "Extreme Fear," and bearishness by most measures was sky high in the days after the April 2 tariff announcement. Now that the stock market is back near its highs, sentiment has turned optimistic again, with CNN's measure flashing "Greed." Because earnings forecasts haven't materially increased, the S&P 500's P/E ratio is north of 21 — hardly cheap. "Valuation multiples expanded in a relief rally from mid-April to now and the S&P 500 now trades at 21x forward earnings, 35% above average," wrote Bank of America analysts to clients on June 14. "The index looks statistically expensive relative to its own history on all 20 of the valuation metrics we track." Doug Kass has tracked the market successfully through 1970s skyrocketing inflation, 1980s double-digit interest rates, the Savings & Loan crisis, the Internet boom and bust, the Great Recession, a pandemic, and the bear market of 2022. He's seen a lot over his nearly 50-year career, making his stock market warning now worth paying attention to. "Equities haven't been this unattractive since late 2021," wrote Kass on TheStreet Pro. "There is little room for disappointment. More Economic Analysis: Hedge-fund manager sees U.S. becoming Greece A critical industry is slamming the economy Reports may show whether the economy is toughing out the tariffs The concern that stocks have priced in much of the good news likely to come from ongoing trade negotiations may have merit, given this week's China trade deal news left tariffs at current levels near 55%. As the impact of tariffs flows through supply chains, inflation may start rising within months, crimping household and business spending. Unfortunately, that's not the only risk on Kass's mind. The money manager provided a long list of threats that could derail stocks' rally. It's a long list, so you may want to refill your beverage. He writes: Political and geopolitical polarization and competition will probably translate into less political centrism and a reduced concern for deficits, creating structural uncertainties, limited fiscal discipline, and imprudence around the globe ... and for the possibility of bond markets to "disanchor." The cracks in the foundation of the bull market are multiple and are deepening, but they are being ignored (as market structure changes have led to price momentum [fear of missing out] being favored over value and common sense). With the S&P 500 Index at around 6000, the downside risk dwarfs the upside reward for equities — in a ratio of about 5-1 (negative). Valuations (a 22-times forward Price Earnings Ratio) and (consensus) expectations for economic and corporate profit growth are all inflated. Being dismissed are JPMorgan CEO Jamie Dimon's and others' dour comments on complacency and a view that the corporate credit market is "ridiculously over-stretched.' Look for the soft data (see last week's weak ISM and climb in jobless claims) to move into (and weaken) the hard data led by a slowing housing market likely to provide ample near-term evidence of the exposure and vulnerability of the middle class. Below trend-line economic growth (housing will lead us lower) coupled with sticky inflation lie ahead ("slugflation") — uncomfortable for a Federal Reserve which has to make increasingly more difficult decisions. Corporate profit growth (rising +13% in 1Q2025) will markedly decelerate in this year's second half. The equity risk premium is at a two-decade low — typically consistent with a slide in equities. The S&P Dividend Yield is at a near-record low of 1.27% — and the spread between the dividend yield and the 10-year U.S. Treasury note yield has rarely been as wide. With so many possible adverse outcomes, my baseline expectation is for seven lean months ahead over the balance of 2025. Kass is clearly nervous that any single or combination of headwinds could cause stocks to give back some gains. What should investors do? Over time, the stock market goes up and to the right, so those with long-term horizons are often best off sticking to their plan, recognizing that there will be bumps and bruises along the way. However, investors with a shorter-term horizon may want to rein in some risk, pocket some profit, and increase "dry powder" to take advantage of any weakness if Kass's warning proves fund manager issues dire stock market warning first appeared on TheStreet on Jun 14, 2025 This story was originally reported by TheStreet on Jun 14, 2025, where it first appeared. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
